Literature DB >> 34250566

Optimizing reconstruction parameters for quantitative 124I-PET in the presence of therapeutic doses of 131I.

Louise M Fanchon1, Bradley J Beattie1, Keith Pentlow1, Steven M Larson2, John L Humm3.   

Abstract

BACKGROUND: The goal of this work was to determine the quantitative accuracy and optimal reconstruction parameters for 124I-PET imaging in the presence of therapeutic levels of 131I. In this effort, images were acquired on a GE D710 PET/CT scanner using a NEMA IEC phantom with spheres containing 124I and increasing amounts of 131I activity in the background. At each activity level, two scans were acquired, one with the phantom centered in the field of view (FOV) and one 11.2 cm off-center. Reconstructions used an ordered subset expectation maximization algorithm with up to 100 iterations of 16 subsets, with and without time-of-flight (TOF) information. Results were evaluated visually and by comparing the 124I activity relative to the scan performed in the absence of 131I.
RESULTS: 131I within the FOV added to the randoms rate, to dead time, and to pile-up within the detectors. Using our standard clinical reconstruction parameters, the image quality and quantitative accuracy suffered at 131I activities above 1.4 GBq. Convergence rates slowed progressively in the presence of increasing amounts of 131I for both TOF and nonTOF reconstructions. TOF reconstructions converged more quickly than nonTOF but often towards erroneous concentrations. Iterating nonTOF reconstructions to convergence produced quantitatively accurate images except for the off-center phantom at the very highest level of background 131I tested.
CONCLUSIONS: This study shows that quantitative PET is feasible in the presence of large amounts of 131I. The high randoms fractions resulted in slow reconstruction convergence and negatively impacted TOF corrections and/or the accuracy of TOF information. Therefore, increased iterations and nonTOF reconstructions are recommended.
© 2021. The Author(s).

Entities:  

Keywords:  Quantitative 124I-PET; Targeted radionuclide therapy; Theragnostic

Year:  2021        PMID: 34250566     DOI: 10.1186/s40658-021-00398-z

Source DB:  PubMed          Journal:  EJNMMI Phys        ISSN: 2197-7364


  11 in total

1.  Quantitative Comparison of 124I PET/CT and 131I SPECT/CT Detectability.

Authors:  Casper Beijst; Jakob W Kist; Mattijs Elschot; Max A Viergever; Otto S Hoekstra; Bart de Keizer; Hugo W A M de Jong
Journal:  J Nucl Med       Date:  2015-10-22       Impact factor: 10.057

2.  Acquisition settings for PET of 124I administered simultaneously with therapeutic amounts of 131I.

Authors:  Mark Lubberink; Annelies van Schie; Hugo W A M de Jong; Guus A M S van Dongen; Gerrit J J Teule
Journal:  J Nucl Med       Date:  2006-08       Impact factor: 10.057

3.  Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software.

Authors:  Katherine S Kolbert; Keith S Pentlow; Joel R Pearson; Arif Sheikh; Ronald D Finn; John L Humm; Steven M Larson
Journal:  J Nucl Med       Date:  2007-01       Impact factor: 10.057

Review 4.  Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer.

Authors:  Lutz S Freudenberg; Walter Jentzen; Alexander Stahl; Andreas Bockisch; Sandra J Rosenbaum-Krumme
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

5.  Impact of high (131)I-activities on quantitative (124)I-PET.

Authors:  P E N Braad; S B Hansen; P F Høilund-Carlsen
Journal:  Phys Med Biol       Date:  2015-06-25       Impact factor: 3.609

Review 6.  Current Treatment Strategies in Metastasized Differentiated Thyroid Cancer.

Authors:  Michael C Kreissl; Marcel J R Janssen; James Nagarajah
Journal:  J Nucl Med       Date:  2018-09-06       Impact factor: 10.057

7.  Patient-specific dosimetry using pretherapy [¹²⁴I]m-iodobenzylguanidine ([¹²⁴I]mIBG) dynamic PET/CT imaging before [¹³¹I]mIBG targeted radionuclide therapy for neuroblastoma.

Authors:  Shih-ying Huang; Wesley E Bolch; Choonsik Lee; Henry F Van Brocklin; Miguel H Pampaloni; Randall A Hawkins; Aimee Sznewajs; Steven G DuBois; Katherine K Matthay; Youngho Seo
Journal:  Mol Imaging Biol       Date:  2015-04       Impact factor: 3.488

8.  A phantom study: Should 124 I-mIBG PET/CT replace 123 I-mIBG SPECT/CT?

Authors:  Casper Beijst; Bart de Keizer; Marnix G E H Lam; Geert O Janssens; Godelieve A M Tytgat; Hugo W A M de Jong
Journal:  Med Phys       Date:  2017-04-17       Impact factor: 4.071

9.  Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels.

Authors:  F Pacini; F Lippi; N Formica; R Elisei; S Anelli; C Ceccarelli; A Pinchera
Journal:  J Nucl Med       Date:  1987-12       Impact factor: 10.057

10.  Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems.

Authors:  Walter Jentzen; Reiner Weise; Jürgen Kupferschläger; Lutz Freudenberg; Wolfgang Brandau; Ronald Bares; Wolfgang Burchert; Andreas Bockisch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-10       Impact factor: 9.236

View more
  1 in total

1.  Efficiency of 124I radioisotope production from natural and enriched tellurium dioxide using 124Te(p,xn)124I reaction.

Authors:  Paweł Bzowski; Damian Borys; Kamil Gorczewski; Agnieszka Chmura; Kinga Daszewska; Izabela Gorczewska; Anna Kastelik-Hryniewiecka; Marcin Szydło; Andrea d'Amico; Maria Sokół
Journal:  EJNMMI Phys       Date:  2022-06-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.